A director at Triplepoint Venture Growth Bdc Corp bought 74,000 shares at 6.661USD and the significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026 STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to September 30, 2026 which is app...
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy STAFFORD, Texas, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided additional updates on FLAMINGO-01 and the Company’s corporate strategy. Corporate Strategy The Company recently attended a Noble Capital conference on December 3, 2025, wher...
Mission Produce® Announces Fiscal 2025 Fourth Quarter and Full Year Financial Results Achieved record full year revenue of $1.39 billion, an increase of 13% year-over-year, driven by strong execution in Marketing & Distribution and significantly higher yields from owned Peruvian orchards in International Farming Generated nearly $180 million in cash flow from operations over the past two years; capital expenditures expected to step down to approximately $40 million in FY26 as Company enters phase of accelerated free cash flow generation Announced leadership succession plan in conjunction ...
Mission Produce® Announces Leadership Succession and Provides Update on Board Refreshment Initiative Founder & CEO Steve Barnard to Transition to Executive Chairman of the Board; President and COO John Pawlowski to Become CEO at the close of the Annual Meeting of Shareholders in April 2026 Board Refreshment Initiative Underway –Three New Independent Directors Appointed in Advance of Expected Retirement of Current Board Chair at close of the Annual Meeting OXNARD, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Mission Produce, Inc. (NASDAQ: AVO) (“Mission” or “the Company”) a world leader in ...
Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01 STAFFORD, Texas, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced an approximately 80% recurrence rate reduction in the open label non-HLA-A*02 arm of FLAMINGO-01. A preliminary analysis of recurrence rates by two methods...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.